LRMR Stock Forecast & Price Target

Larimar Therapeutics Inc has demonstrated a significant increase in median skin frataxin (FXN) expression, rising from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, surpassing the levels found in over 50% of healthy volunteers. Additionally, the company reported a median improvement in the modified Friedreich Ataxia Rating Scale (mFARS) of -2.20 points after one year, in contrast to a decline of +1.00 points observed in the FACOMS natural history population. These positive outcomes indicative of effective treatment responses provide a solid foundation for a favorable outlook on the company's future in managing Friedreich's ataxia.

Larimar Therapeutics Inc. faces a challenging outlook due to a significant decline in projected revenue estimates, with the FY29 estimate revised downward from $659 million to $407 million, indicating potential issues in achieving market penetration despite an anticipated 25% market share in the U.S. Friedreich's ataxia market. Additionally, the clinical data reveals a concerning median change in the modified Friedreich's Ataxia Rating Scale (mFARS), showing a decline of -2.20 points, which contrasts unfavorably with a +1.00 point decline in the FACOMS natural history population at one year. This discrepancy raises doubts about the efficacy of Larimar's lead candidate, CTI-1601, which could hinder investor confidence and negatively impact stock performance.